OR23-03 Sustained Normalization Of Mineral Homeostasis In Autosomal Dominant Hypocalcemia Type 1: Results From A Phase 2 Study Over 18 Months Of Encaleret (CLTX-305) Treatment (NCT04581629)

Disclosure: R.I. Gafni: Advisory Board Member; Self; Ascendis Pharma, Hypoparathyroidism Association. Grant Recipient; Self; Calcilytix Therapeutics. I.R. Hartley: Grant Recipient; Self; Calcilytix Therapeutics. K.L. Roszko: Grant Recipient; Self; Calcilytix Therapeutics. E.F. Nemeth: Consulting Fee...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilana Gafni, Rachel, Ruth Hartley, Iris, Lauter Roszko, Kelly, Nemeth, Edward F, Pozo, Karen A, Mathew, Arun, Scott Roberts, Mary, Adler, Scott H, Collins, Michael T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Bone And Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554279/
http://dx.doi.org/10.1210/jendso/bvad114.561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554279/
http://dx.doi.org/10.1210/jendso/bvad114.561

Ejemplares similares